Current market
Where commercial-stage psychedelic companies stand today.
The difference between research-stage and commercial-stage, where revenue comes from, and how Optimi fits among the public comparables.
01The taxonomyWhere Optimi sits
| Company | Exchange | Stage | Focus | Note |
|---|---|---|---|---|
| Optimi Health Corp. | CSE:OPTI · OTCQX:OPTHF | Commercial | GMP psilocybin + MDMA supply | Revenue-generating via regulated access programs; Health Canada DEL holder. |
| Compass Pathways plc | NASDAQ:CMPS | Late clinical | Synthetic psilocybin (COMP360) for TRD | COMP005 + COMP006 Phase 3 trials both hit primary endpoint; NDA submission expected Q4 2026. Drug-developer model, not commercial supplier. |
| AtaiBeckley Inc. | NASDAQ:ATAI | Late clinical | BPL-003 (mebufotenin nasal) for TRD | Formed by 2025 merger of atai Life Sciences and Beckley Psytech; redomiciled to U.S. BPL-003 Phase 3 starts Q2 2026 (FDA Breakthrough Therapy designation). |
| Cybin Inc. | NYSE-A:CYBN | Late clinical | Deuterated psilocin CYB003 (MDD) | PARADIGM/APPROACH Phase 3 enrolling; topline data expected Q4 2026. CYB004 (deuterated DMT) Phase 2 GAD data Q1 2026. |
| Definium Therapeutics, Inc. | NASDAQ:DFTX | Late clinical | DT120 ODT (lysergide d-tartrate) for GAD + MDD | Rebranded from MindMed (formerly NASDAQ:MNMD) in January 2026; three Phase 3 readouts expected in 2026. |
02Market shape
2
National commercial frameworks
Australia (TGA Authorised Prescriber Scheme, 2023) and Canada (Special Access Program, 2020) — the only two countries with population-level commercial access to psilocybin and MDMA in 2026.
100M+
TRD patients globally
WHO data on major depression cited above; ~30–40% of MDD patients meet treatment-resistant criteria. The market is gated by access frameworks and prescribers, not patient demand.
0
FDA-approved psychedelic medicines
Pre-1985 MDMA was unscheduled; today, no psilocybin or MDMA product is FDA-approved. Lykos's 2024 NDA was declined; Compass Pathways targets a 2026 NDA submission.
03The thesis
Commercial-stage psychedelic companies are rare. Most public comparables are still drug developers — they burn capital through clinical trials and have not yet crossed into revenue-generating supply. Optimi's differentiation is that it is already a manufacturer and supplier to regulated access programs. The investor question shifts from "will the asset read out?" to "how fast does regulated access expand, and how defensible is the manufacturing position when it does?"